$QURE

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Barclays downgraded uniQure (QURE) from Overweight to Equal-Weight, lowering its price target from $60.00 to $28.00. The company's GF Value™ is $7.94, suggesting it's 195.5% overvalued. uniQure has a GF Score™ of 49/100, indicating mixed financial performance. Analysts cite concerns over financial health and market conditions.

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.

uniQure (QURE) shared updated Phase I/II data for AMT-130, showing slowed Huntington’s disease progression. The FDA indicated 36-month high-dose data could support accelerated approval. The company focuses on gene therapies for rare conditions, with AMT-130 as a key catalyst.

AstraZeneca invested $2B in Summit Therapeutics, boosting its shares 16%. UniQure's stock fell 40% after 4-year trial data for its Huntington's disease therapy showed slower progression than earlier results. The FDA recently approved drugs from AbbVie, Eli Lilly, Merck, and Mirum. Kyverna's CAR T therapy showed positive results for stiff person syndrome, with an FDA submission expected by year-end.

uniQure (QURE) shares fell 37% after four-year Huntington’s gene therapy study results missed a key test, though three-year data showed significant slowing of disease decline. Analysts maintained bullish ratings, citing strong three-year results and potential FDA approval. The stock closed at $24.51, its worst day since November 2025.

uniQure reported 48-month data for AMT-130, its gene therapy for Huntington's disease. The study showed a 44% slowing of cUHDRS decline and a 61% slowing on TFC, with the latter reaching statistical significance. The company noted differences in external-control datasets and conducted sensitivity analyses. AMT-130 was generally well-tolerated, with no new serious adverse events. uniQure's BLA submission is based on 36-month data, and the company awaits FDA review.

uniQure N.V. [QURE] reported that its AMT-130 treatment showed sustained slowing of Huntington's disease progression at 36 and 48 months, with improvements in functional capacity and a favorable safety profile. The company highlighted the stability in Total Functional Capacity (TFC) as clinically meaningful and announced that regulatory submissions are advancing.

Dow Jones fell 100 points, while Carnival (CCL) reported Q3 earnings of $1.43 per share, beating estimates. NASDAQ and S&P 500 also saw mixed trading. BIO-Key (BKYI) and SoundThinking (SSTI) shares surged on strategic news. NewGenIvf (NIVF) and Triller (ILLR) shares dropped significantly.

uniQure's stock fell 41% after its Huntington’s disease gene therapy, AMT-130, showed a 44% slowing of disease progression at 48 months, missing statistical significance. Despite this, analysts and the company remain optimistic due to a strong secondary endpoint and questions about the primary endpoint's comparator data. The FDA's response to the new data remains uncertain.